MY181496A - Smoothened polypeptides and methods of use - Google Patents

Smoothened polypeptides and methods of use

Info

Publication number
MY181496A
MY181496A MYPI2013000956A MYPI2013000956A MY181496A MY 181496 A MY181496 A MY 181496A MY PI2013000956 A MYPI2013000956 A MY PI2013000956A MY PI2013000956 A MYPI2013000956 A MY PI2013000956A MY 181496 A MY181496 A MY 181496A
Authority
MY
Malaysia
Prior art keywords
functional fragment
inhibiting
functional
treating
methods
Prior art date
Application number
MYPI2013000956A
Other languages
English (en)
Inventor
Nadya Tarasova
Michael Dean
Hong Lou
Original Assignee
Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services filed Critical Government Of The United States Of America Represented By The Sec Dep Of Health And Human Services
Publication of MY181496A publication Critical patent/MY181496A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MYPI2013000956A 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use MY181496A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85542206P 2006-10-31 2006-10-31

Publications (1)

Publication Number Publication Date
MY181496A true MY181496A (en) 2020-12-23

Family

ID=39492945

Family Applications (2)

Application Number Title Priority Date Filing Date
MYPI2013000956A MY181496A (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use
MYPI20091748A MY149170A (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
MYPI20091748A MY149170A (en) 2006-10-31 2007-10-30 Smoothened polypeptides and methods of use

Country Status (13)

Country Link
US (3) US8198402B2 (cg-RX-API-DMAC7.html)
EP (2) EP2078036A2 (cg-RX-API-DMAC7.html)
JP (3) JP5399255B2 (cg-RX-API-DMAC7.html)
KR (1) KR101563010B1 (cg-RX-API-DMAC7.html)
CN (2) CN103435694A (cg-RX-API-DMAC7.html)
AU (1) AU2007329678A1 (cg-RX-API-DMAC7.html)
CA (1) CA2667821A1 (cg-RX-API-DMAC7.html)
MY (2) MY181496A (cg-RX-API-DMAC7.html)
NZ (1) NZ576467A (cg-RX-API-DMAC7.html)
PH (1) PH12013502425A1 (cg-RX-API-DMAC7.html)
SG (2) SG178743A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008070357A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200902894B (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008070357A2 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use
TWI433674B (zh) 2006-12-28 2014-04-11 Infinity Discovery Inc 環杷明（ｃｙｃｌｏｐａｍｉｎｅ）類似物類
WO2009086451A1 (en) 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Methods for stereoselective reduction
AU2008345151A1 (en) * 2007-12-27 2009-07-09 Infinity Pharmaceuticals, Inc. Therapeutic cancer treatments
US20100297118A1 (en) * 2007-12-27 2010-11-25 Macdougall John Therapeutic Cancer Treatments
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2462115B1 (en) 2009-08-05 2016-01-06 Infinity Pharmaceuticals, Inc. Enzymatic transamination of cyclopamine analogs
WO2011088404A1 (en) * 2010-01-15 2011-07-21 Infinity Pharmaceuticals , Inc Treatment of fibrotic conditions using hedgehog inhibitors
WO2011146882A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
US9394313B2 (en) 2010-09-14 2016-07-19 Infinity Pharmaceuticals, Inc. Transfer hydrogenation of cyclopamine analogs
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
EP2663309B1 (en) 2011-01-10 2017-03-15 Infinity Pharmaceuticals, Inc. Processes for preparing isoquinolinones and solid forms of isoquinolinones
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013012918A1 (en) 2011-07-19 2013-01-24 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
CA2846431A1 (en) 2011-08-29 2013-03-07 Infinity Pharmaceuticals Inc. Heterocyclic compounds and uses thereof
US9630979B2 (en) 2011-09-29 2017-04-25 Infinity Pharmaceuticals, Inc. Inhibitors of monoacylglycerol lipase and methods of their use
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX375194B (es) 2012-11-01 2025-03-06 Infinity Pharmaceuticals Inc Tratamiento de cánceres utilizando moduladores de las isoformas de pi3 cinasa.
CA2893133A1 (en) 2012-11-29 2014-06-05 Strasspharma Llc Methods of modulating follicle stimulating hormone activity
US20160024051A1 (en) 2013-03-15 2016-01-28 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9192609B2 (en) 2013-04-17 2015-11-24 Hedgepath Pharmaceuticals, Inc. Treatment and prognostic monitoring of proliferation disorders using hedgehog pathway inhibitors
DK3003309T3 (da) 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
SG10201902074UA (en) 2013-10-04 2019-04-29 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015061204A1 (en) 2013-10-21 2015-04-30 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3119397T (pt) 2014-03-19 2022-04-11 Infinity Pharmaceuticals Inc Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
US20150320754A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2015168079A1 (en) 2014-04-29 2015-11-05 Infinity Pharmaceuticals, Inc. Pyrimidine or pyridine derivatives useful as pi3k inhibitors
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR101723649B1 (ko) 2014-10-23 2017-04-06 서울대학교산학협력단 신규한 펩티드 화합물, 이의 생산 방법, 및 이의 용도
CA2988289C (en) 2015-06-04 2023-12-05 PellePharm, Inc. Topical formulations for delivery of hedgehog inhibitor compounds and use thereof
KR102787845B1 (ko) 2015-09-14 2025-03-31 트웰브 테라퓨틱스, 아이엔씨. 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
US20170231968A1 (en) 2016-02-11 2017-08-17 PellePharm, Inc. Method for relief of and treatment of pruritus
JP6889432B2 (ja) * 2016-04-28 2021-06-18 学校法人甲南学園 樹脂固定ペプチド
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN109640999A (zh) 2016-06-24 2019-04-16 无限药品股份有限公司 组合疗法
US20200231642A1 (en) * 2017-02-19 2020-07-23 The National Institute for Biotechnology in the Negev Ltd. Peptide kinase inhibitors and methods of use thereof
CN108644311B (zh) * 2018-05-22 2019-09-06 东北大学 一种基于硬化立方刚度吸振器实现方法及吸振器

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
IN165717B (cg-RX-API-DMAC7.html) 1986-08-07 1989-12-23 Battelle Memorial Institute
JP3266311B2 (ja) 1991-05-02 2002-03-18 生化学工業株式会社 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
WO1999001468A2 (en) 1997-07-01 1999-01-14 Ontogeny, Inc. Vertebrate smoothened gene, gene products, and uses related thereto
IL125608A0 (en) * 1998-07-30 1999-03-12 Yeda Res & Dev Tumor associated antigen peptides and use of same as anti-tumor vaccines
US6683192B2 (en) * 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
JP5356636B2 (ja) * 2000-04-21 2013-12-04 タフツ メディカル センター インコーポレイテッド Ｇタンパク質共役型受容体（ｇｐｃｒ）のアゴニストおよびアンタゴニスト、および、それらを用いてｇｐｃｒを活性化および阻害する方法
DE60113733T2 (de) * 2001-07-02 2006-06-29 Tas, Sinan Verwendung von cyclopamine, zur behandlung des basalzellkarzinoms und anderer tumoren
MXPA04000803A (es) * 2001-07-27 2004-05-21 Curis Inc Mediadores de rutas de senalizacion de hedgehog, composiciones y usos relacionados a los mismos.
JP2007527503A (ja) * 2003-06-17 2007-09-27 プロノタ・エヌブイ ペプチドコンボ及びそれらの使用
EP1814911A2 (en) * 2004-11-04 2007-08-08 New England Medical Center Hospitals, Inc. G protein coupled receptor agonists and antagonists and methods of use
US8088976B2 (en) * 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
WO2007134272A2 (en) * 2006-05-12 2007-11-22 Janssen Pharmaceutica N.V. Humanized models via targeted mtagenesis with zinc finger nuclease
WO2008070357A2 (en) * 2006-10-31 2008-06-12 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Smoothened polypeptides and methods of use

Also Published As

Publication number Publication date
US8198402B2 (en) 2012-06-12
CN103435694A (zh) 2013-12-11
US20120282196A1 (en) 2012-11-08
KR101563010B1 (ko) 2015-10-26
CN101616931A (zh) 2009-12-30
NZ576467A (en) 2012-03-30
US20130316957A1 (en) 2013-11-28
US20100093625A1 (en) 2010-04-15
WO2008070357A9 (en) 2008-08-14
JP5399255B2 (ja) 2014-01-29
US8546524B2 (en) 2013-10-01
JP5739484B2 (ja) 2015-06-24
SG178743A1 (en) 2012-03-29
PH12013502425B1 (en) 2014-10-27
CA2667821A1 (en) 2008-06-12
KR20090084839A (ko) 2009-08-05
PH12013502425A1 (en) 2014-10-27
EP2431388A1 (en) 2012-03-21
WO2008070357A2 (en) 2008-06-12
AU2007329678A1 (en) 2008-06-12
SG175691A1 (en) 2011-11-28
CN101616931B (zh) 2013-08-21
JP2015180630A (ja) 2015-10-15
ZA200902894B (en) 2010-04-28
JP2013255500A (ja) 2013-12-26
HK1137031A1 (en) 2010-07-16
MY149170A (en) 2013-07-31
JP2010508305A (ja) 2010-03-18
EP2078036A2 (en) 2009-07-15
WO2008070357A3 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
MY181496A (en) Smoothened polypeptides and methods of use
IN2012DN02981A (cg-RX-API-DMAC7.html)
CY1121132T1 (el) ΠΛΗΡΩΣ-ΑΝΘΡΩΠΙΝΑ ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ ANTI-vap-1
MX2024005677A (es) Receptores de celulas t que reconocen p53 mutado.
DK1641818T3 (da) Polypeptider der har bindingsaffinitet for HER2
WO2011036442A3 (en) Thrombin c- terminal polypeptides and uses thereof for treating inflammation coagulation disorders
MX2022010175A (es) Proteinas de union a flt3 y metodos de uso.
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
CN105848667A (zh) 具有血管生成抑制活性的肽和包含所述肽的组合物
BRPI0416744A (pt) sistemas de expressão de proteìna aperfeiçoados
MX2021015877A (es) Receptores de celulas t que reconocen la mutacion r175h o y220c en p53.
WO2003087768A3 (en) Targets for therapeutic intervention identified in the mitochondrial proteome
EA201170993A1 (ru) Удлиненные рекомбинантные полипептиды и содержащие их композиции
WO2012061683A3 (en) Methods for treating cancer
WO2020186207A3 (en) Non-viral dna vectors and uses thereof for expressing fviii therapeutics
WO2006090810A3 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
MX2020013296A (es) Composiciones que contienen inhibidor de proteasa recombinante, metodos para producir las mismas y usos de las mismas.
ATE494381T1 (de) Verbesserte expressionselemente
WO2008040190A8 (fr) Petits peptides pour anti-angiogenèse et utilisation de ceux-ci
ATE473283T1 (de) Dna-expressionsvektoren
BR0009170A (pt) ácidos nucléicos akt, polipeptìdeos e uso dos mesmos
MX2025007855A (es) Proteina triespecifica dirigida a trop2 para el tratamiento del cancer
NZ603611A (en) Insulin-like growth factor 1 receptor binding peptides
WO2005123760A3 (en) Treating cancer
CY1111004T1 (el) Χρησιμες συνθεσεις για τη ρυθμιση της δρασης του γονιδιου της παρκινης